ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma We conducted ...
The Department of Telecommunications (DoT) has officially notified the de-licensing of 500 megahertz of spectrum in the lower-frequency range of the 6 GHz band, a move expected to significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results